Verrica Pharmaceuticals Announces Acceptance of Abstract Featuring Clinical Data of VP-315 for the Treatment of Basal Cell Carcinoma at the American Academy of Dermatology Association’s (AAD) 2023 Innovation Academy Meeting
August 03, 2023 07:30 ET
|
Verrica Pharmaceuticals Inc.
WEST CHESTER, Pa., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin...
Verrica Pharmaceuticals Announces Closing of $125 Million Debt Financing with OrbiMed
July 26, 2023 16:05 ET
|
Verrica Pharmaceuticals Inc.
– Verrica received $50M upon the close of the transaction; $75M of additional capital available in tranches based on the achievement of certain revenue milestones – – Proceeds from the transaction to...
Following FDA Approval of YCANTH™ for the Treatment of Molluscum Contagiosum, Verrica Pharmaceuticals Enters into Non-Binding Term Sheet for up to $125 Million Debt Financing; Company to Host Conference Call and Webcast This Morning at 8:30 am ET
July 24, 2023 07:00 ET
|
Verrica Pharmaceuticals Inc.
Term loan facility would provide for up to $125M in non-dilutive capital; $50M immediately available to Company following close of the transaction, which is expected to occur by the end of this week...
Verrica Pharmaceuticals Announces FDA Approval of YCANTH™ (cantharidin) topical solution as the First FDA approved Treatment of Pediatric and Adult Patients with Molluscum Contagiosum
July 21, 2023 16:24 ET
|
Verrica Pharmaceuticals Inc.
– Molluscum, is a highly contagious viral skin infection affecting approximately 6 million people annually in the United States, primarily children – – YCANTH™ is a drug-device combination product...
Verrica Pharmaceuticals Announces Presentation at the Jefferies Healthcare Conference in New York
May 31, 2023 07:00 ET
|
Verrica Pharmaceuticals Inc.
WEST CHESTER, Pa., May 31, 2023 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin...
Verrica Pharmaceuticals Announces Presentation at the RBC Capital Markets Global Healthcare Conference
May 10, 2023 07:30 ET
|
Verrica Pharmaceuticals Inc.
WEST CHESTER, Pa., May 10, 2023 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin...
Verrica Pharmaceuticals Reports First Quarter 2023 Financial Results
May 09, 2023 07:30 ET
|
Verrica Pharmaceuticals Inc.
New Drug Application for YCANTH™ (VP-102) PDUFA Goal Date of July 23, 2023 - Potential to Become Only FDA-approved Therapy for Treatment of Molluscum Contagiosum Raised Gross Proceeds of $32.5...
Verrica Pharmaceuticals Announces Dosing of the First Patient in Part 2 of Phase 2 Study Evaluating VP-315 for the Treatment of Basal Cell Carcinoma
April 12, 2023 07:00 ET
|
Verrica Pharmaceuticals Inc.
WEST CHESTER, Pa., April 12, 2023 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or, the “Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin...
Verrica Pharmaceuticals Announces Presentation at the 22nd Annual Needham Virtual Healthcare Conference
April 11, 2023 07:00 ET
|
Verrica Pharmaceuticals Inc.
WEST CHESTER, Pa., April 11, 2023 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring...
Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2022 Financial Results
March 06, 2023 07:30 ET
|
Verrica Pharmaceuticals Inc.
New Drug Application for VP-102 assigned PDUFA goal date of July 23, 2023 VP-102 has potential to address the approximately six million patients in the U.S. with molluscum contagiosum Dosing of...